US2021236637A1PendingUtilityA1

Sensitizing composition using electromagnetic waves for thermal therapy of cancers, and cancer therapy using same

57
Assignee: JINIS CO LTDPriority: Oct 16, 2013Filed: Mar 31, 2021Published: Aug 5, 2021
Est. expiryOct 16, 2033(~7.3 yrs left)· nominal 20-yr term from priority
A61K 33/26A61P 43/00A61K 33/24A61N 2005/0662A61K 41/0052A61N 2005/0659A61K 33/06A61N 5/02A61N 2005/1098A61N 2005/0661A61N 5/062A61K 45/06A61K 38/40A61P 35/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, “metal ion-noncovalently bound apotransferrin” (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.

Claims

exact text as granted — not AI-modified
1 . A composition for thermal cancer therapy, comprising:
 (i) a sensitizer for thermal therapy, having targetability to cancer tissues and, when cancer tissues are exposed to electromagnetic waves, amplifying generation of heat; and   (ii) water as a pharmaceutically acceptable carrier,   wherein the sensitizer for thermal therapy comprises a metal ion-carbohydrate complex in which (a) a metal ion selected from the group consisting of an iron ion and a magnesium ion is noncovalently bound to (b) a binding material selected from the group consisting of dextran, carboxymaltose, isomaltoside, and starch.   
     
     
         2 . The composition for thermal cancer therapy according to  claim 1 , wherein the sensitizer has a concentration of 0.01 to 100 mg/ml. 
     
     
         3 . A thermal cancer therapy kit, comprising:
 the composition of  claim 1  for thermal cancer therapy; and   a device for applying electromagnetic waves.   
     
     
         4 . A method of treating cancer in an animal in need thereof, comprising:
 (a) administering the composition of  claim 1  for thermal cancer therapy to the animal, thus increasing sensitivity to cancer treatment; and   (b) applying electromagnetic waves.   
     
     
         5 . The method according to  claim 4 , wherein the sensitizer is administered in a dose of 0.1 to 50 mg/kg. 
     
     
         6 . The method according to  claim 4 , wherein the electromagnetic waves are selected from the group consisting of gamma rays, X-rays, UV rays, visible light, IR light, microwaves, and radio waves. 
     
     
         7 . The method according to  claim 4 , wherein the method is performed in combination with at least one therapy selected from the group consisting of chemotherapy, radiation therapy, biological therapy, immunotherapy, and photodynamic therapy.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.